CLPT, a company in the healthcare industry, has been on the rise despite a recent earnings miss. The last earnings report on December 31st showed a lower earnings per share than expected, but the company has since shown promising technical indicators.
With a P/B Ratio of 6.231 and a P/E Ratio of 0.000, CLPT is on par with comparable stocks in the industry. The PEG Ratio, which measures projected growth, is also within normal values. Although the company does not offer a dividend, the P/S Ratio is in line with the average among similar stocks.
One standout factor for CLPT is its recent upward trend. On April 6th, 2023, the stock moved above its 50-day moving average, indicating a change from a downward trend to an upward trend. In fact, A.I.dvisor has found that in 37 of 41 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are currently at 90%.
Interestingly, A.I.dvisor also suggests a loose correlation between CLPT and another healthcare stock, OPK. These tickers have moved in lockstep 51% of the time over the past year, indicating a potential price increase for OPK if CLPT continues its upward trend.
While the recent earnings miss may have initially caused concern for investors, the positive technical indicators and upward trend suggest that CLPT is still a promising investment opportunity. As always, it is important to do your own research and consider all factors before making any investment decisions.
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where CLPT advanced for three days, in 217 of 272 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CLPT's RSI Oscillator exited the oversold zone, 27 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
CLPT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on September 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CLPT as a result. In 82 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
The Moving Average Convergence Divergence Histogram (MACD) for CLPT turned negative on September 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 53 similar instances when the indicator turned negative. In 46 of the 53 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.
CLPT moved below its 50-day moving average on September 29, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLPT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for CLPT entered a downward trend on October 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 60 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CLPT's P/B Ratio (43.290) is slightly higher than the industry average of (10.853). P/E Ratio (0.000) is within average values for comparable stocks, (98.910). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (9.268) is also within normal values, averaging (39.828).
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. CLPT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLPT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a company, which engages in the development and commercialization of innovative platforms for performing minimally invasive surgical procedures in the brain and heart.
Industry MedicalNursingServices